The next question is “What type of clinical result is foreseeable for any treatment aimed at de novo production of dystrophin in DMD patients?” A complete, long-lasting restoration of dystrophin around all of the residual myofibers in DMD patients is too optimistic. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.